Gender Female
LinkedIn View on LinkedIn
Dr. Liou is a co-founder of ImmuneTarget, and previously served as ImmuneTarget CEO from its inception until 2015.
She received a Ph.D. from Harvard University in 1989 under the supervision of Dr. Laurie H. Glimcher, and completed a post-doctural fellowship at MIT and Rockefeller University under the direction of Dr. David Baltimore. She
subsequently held a faculty position from 1994 to 2011 at the Weill Medical College of Cornell University, where she received over $6 million in federal and private funding to pioneer research in molecular biology, cell biology, and immunology. Her team generated one of the c-Rel knockout mouse models and discovered the NF-kB/Rel inhibitors.Dr. Liou's experience also extends to finance and investments. She is a CFA charterholder and served as an equity analyst at Biovantage Investments from 2012 to 2014. As a portfolio advisor at Bank of America Merrill Lynch, she manages investment portfolios for executives of biotech companies and professionals in the healthcare industry.
Dr. Liou has been the recipient of many prestigious awards, including the Scholar Award by the Leukemia and Lymphoma Society, the Junior Faculty Research Award by the American Cancer Society, the Basil O'Connor Scholar award by the March of Dimes Foundation, the First Prize winner for the Medicine Investigator Award sponsored by the Michael Wolk Heart Foundation, and the Government Scholarship Award of Biotechnology for Overseas Study (Taiwan).
